|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C15H16BrN5O6 |
|||
| Molecular Weight | 442.22 | CAS No. | 70359-46-5 | |
| Solubility (25°C)* | In vitro | DMSO | 88 mg/mL (198.99 mM) | |
| Water | 75 mg/mL (169.59 mM) | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Brimonidine Tartrate(UK 1434 Tartrate) is a highly selective α-adrenergic receptor agonist with EC50 of 0.45 nM for the α2A adrenoreceptor, and used to treat open-angle glaucoma or ocular hypertension. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | Brimonidine reduces the progressive loss of ganglion cells to 26% and 15% at doses of 0.5 mg/kg and 1 mg/kg, respectively. Brimonidine administration initiates 10 days after IOP elevation prevents any further loss of ganglion cells. Brimonidine attenuates the increase in immunoreactivity of GFAP in ocular hypertensive retinas. Brimonidine, but not timolol, shows significant protection of retinal ganglion cells when applied at the time of intraocular pressure (IOP) elevation and prevents further cell loss when applied after intraocular pressure (IOP) is elevated. [1] Brimonidine injected intravitreally into Sprague-Dawley rat eyes increases the number of BDNF-positive RGCs from 55% to 166%. [2] Brimonidine 0.5% given as one drop before, after, or both before and after 360 degrees argon laser trabeculoplasty significantly lowers the incidence of postlaser IOP spikes. Brimonidine 0.2% instilled twice daily offers long-term IOP control comparable with that achieved with timolol 0.5% and better than betatolol 0.25% suspension. [3] |
||
| In vivo | Brimonidine (1 mg/kg) significantly protects RGCs from elevated IOP-induced cell death in adult rats. [4] Brimonidine (0.0001%) BMD results in the loss of approximately 37% of the retinal ganglion cell (RGC) population and has no significant neuroprotective effects in adult Sprague-Dawley rats. Brimonidine (0.001% or 0.01%) results in the survival of 76 or 90%, respectively, of the RGC population, and 0.1% Brimonidine fully prevents retinal ganglion cell (RGC) death in the first 7 days after ischemia in adult Sprague-Dawley rats. [5] |
Protocol (from reference)
References
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.